Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Cancer Research / A Human Peripheral Blood Mononuclear Cell (PBMC)…
JoVE Journal
Cancer Research

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Cancer Research
A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research (A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research (A-O)
The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Journal (Cancer Research)
The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Morphology-Based Distinction Between Healthy and Pathological Cells Utilizing Fourier Transforms and Self-Organizing Maps
Journal (Cancer Research)
Morphology-Based Distinction Between Healthy and Pathological Cells Utilizing Fourier Transforms and Self-Organizing Maps
 
Click here for the English version

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research (A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research (A-O)

Article DOI: 10.3791/59679-v • 08:17 min • August 15th, 2019
August 15th, 2019 •
*1, *1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1
1BeiGene (Beijing) Co., Ltd.
* These authors contributed equally

Chapters

Summary
Automatic Translation

Please note that all translations are automatically generated.

Click here for the English version.

Nous décrivons une cellule mononucléaire périphérique humaine de sang (PBMC) — modèle humanisé basé de souris de xénogreffe pour la recherche translationnelle d'immuno-oncologie. Ce protocole pourrait servir de ligne directrice générale pour établir et caractériser des modèles similaires pour l'évaluation de la thérapie I-O.

Tags

Rétraction Numéro 150 immuno-oncologie (I-O) cellule mononucléaire sanguine périphérique (PBMC) Tislelizumab BGB-A317 immunodéficient humanisé cyclophosphamide (CP) xénogreffe dérivée du patient (PDX)
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter